Protalix BioTherapeutics (PLX) Cash from Financing Activities (2010 - 2026)

Protalix BioTherapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $150000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 97.04% year-over-year to $150000.0 in Q1 2026; TTM through Mar 2026 was $4.4 million, a 49.44% decrease from a year earlier, with the FY2025 full-year figure at $9.3 million, up 155.53% from the prior year.
• Cash from Financing Activities climbed to $150000.0 in Q1 2026 per PLX's latest filing, from $146000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $14.2 million in Q1 2023 and bottomed at $146000.0 in Q4 2025.
• The 5-year median for Cash from Financing Activities is $4.1 million (2022), against an average of $4.8 million.
• Across the five-year window, Cash from Financing Activities surged 200.72% in 2022 and tumbled 97.04% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $4.1 million in 2022, then soared by 156.02% to $10.4 million in 2023, then sank by 65.24% to $3.6 million in 2024, then slumped by 95.97% to $146000.0 in 2025, then climbed by 2.74% to $150000.0 in 2026.
• Per Business Quant, the three latest PLX Cash from Financing Activities figures stand at $150000.0 (Q1 2026), $146000.0 (Q4 2025), and $4.1 million (Q2 2025).